Stock listing
PYPD Stock Price, News, Filings & Events — Polypid Ltd.
Selected listing: PYPD · NASDAQ · USD · US
This page tracks Polypid Ltd.'s PYPD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PYPD:NASDAQ. PYPD:NASDAQ is the stock-level entry point for investors researching Polypid Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Polypid Ltd. is a public company traded under the ticker PYPD in the American market. The company has a market capitalization of approximately $102.5 million. Polypid focuses on developing innovative drug delivery systems to improve patient outcomes.
- Ticker
- PYPD:NASDAQ
- Asset type
- Stock
- Market cap
- $90.5M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Polypid Ltd. PYPD:NASDAQ stock context
This page tracks Polypid Ltd.'s PYPD:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following PYPD:NASDAQ. PYPD:NASDAQ is the stock-level entry point for investors researching Polypid Ltd., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Polypid Ltd. is a public company traded under the ticker PYPD in the American market. The company has a market capitalization of approximately $102.5 million. Polypid focuses on developing innovative drug delivery systems to improve patient outcomes.
Latest news from Polypid Ltd.
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 12, 2026
PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD)
July 31, 2026
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
July 30, 2026
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
July 29, 2026
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
July 21, 2026
Polypid Ltd. earnings calls
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call
August 12, 2026 · Replay with transcript and chapters
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call
May 13, 2026 · Replay with transcript and chapters
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call
February 11, 2026 · Replay with transcript and chapters
PolyPid Ltd. (PYPD) Q3 2025 Earnings Call
November 12, 2025 · Replay with transcript and chapters
PolyPid Ltd. (PYPD) Q2 2025 Earnings Call
August 13, 2025 · Replay with transcript and chapters
PolyPid Ltd. (PYPD) Q1 2025 Earnings Call
May 14, 2025 · Replay with transcript and chapters
Research Polypid Ltd.
Polypid Ltd. investor report
Review AI stock analysis and investor report context for PYPD:NASDAQ.
Polypid Ltd. company profile
View the public company page for Polypid Ltd. on 6ix.
Polypid Ltd. news
Read company news and market updates connected to Polypid Ltd..
Polypid Ltd. investor events
Find investor webinars, events, and replay context for Polypid Ltd..